![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TICAM1 |
Gene summary for TICAM1 |
![]() |
Gene information | Species | Human | Gene symbol | TICAM1 | Gene ID | 148022 |
Gene name | toll like receptor adaptor molecule 1 | |
Gene Alias | IIAE6 | |
Cytomap | 19p13.3 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q8IUC6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
148022 | TICAM1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.50e-07 | 3.84e-01 | -0.1808 |
148022 | TICAM1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.13e-06 | 4.09e-01 | -0.0811 |
148022 | TICAM1 | HTA11_347_2000001011 | Human | Colorectum | AD | 6.56e-03 | 2.11e-01 | -0.1954 |
148022 | TICAM1 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.40e-06 | 1.12e+00 | -0.2602 |
148022 | TICAM1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.73e-02 | 8.10e-01 | -0.2196 |
148022 | TICAM1 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.87e-05 | 2.48e-01 | -0.1464 |
148022 | TICAM1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 9.98e-11 | 5.02e-01 | -0.059 |
148022 | TICAM1 | HTA11_546_2000001011 | Human | Colorectum | AD | 3.12e-03 | 3.03e-01 | -0.0842 |
148022 | TICAM1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.03e-07 | 3.15e-01 | 0.0674 |
148022 | TICAM1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.03e-02 | 2.55e-01 | 0.3859 |
148022 | TICAM1 | LZE4T | Human | Esophagus | ESCC | 2.68e-06 | 1.84e-01 | 0.0811 |
148022 | TICAM1 | LZE7T | Human | Esophagus | ESCC | 9.65e-07 | 2.50e-01 | 0.0667 |
148022 | TICAM1 | LZE8T | Human | Esophagus | ESCC | 5.10e-11 | 3.65e-01 | 0.067 |
148022 | TICAM1 | LZE20T | Human | Esophagus | ESCC | 3.64e-06 | 1.89e-01 | 0.0662 |
148022 | TICAM1 | LZE22T | Human | Esophagus | ESCC | 3.19e-02 | 5.83e-01 | 0.068 |
148022 | TICAM1 | LZE24T | Human | Esophagus | ESCC | 8.32e-34 | 1.13e+00 | 0.0596 |
148022 | TICAM1 | LZE21T | Human | Esophagus | ESCC | 2.04e-09 | 6.42e-01 | 0.0655 |
148022 | TICAM1 | P1T-E | Human | Esophagus | ESCC | 1.17e-05 | 9.20e-01 | 0.0875 |
148022 | TICAM1 | P2T-E | Human | Esophagus | ESCC | 5.11e-07 | 9.30e-02 | 0.1177 |
148022 | TICAM1 | P4T-E | Human | Esophagus | ESCC | 2.89e-11 | 2.70e-01 | 0.1323 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000680915 | Oral cavity | OSCC | nitric oxide biosynthetic process | 41/7305 | 76/18723 | 5.78e-03 | 2.22e-02 | 41 |
GO:00714022 | Oral cavity | OSCC | cellular response to lipoprotein particle stimulus | 22/7305 | 36/18723 | 5.96e-03 | 2.27e-02 | 22 |
GO:0002888 | Oral cavity | OSCC | positive regulation of myeloid leukocyte mediated immunity | 13/7305 | 19/18723 | 9.07e-03 | 3.26e-02 | 13 |
GO:200105715 | Oral cavity | OSCC | reactive nitrogen species metabolic process | 43/7305 | 82/18723 | 9.20e-03 | 3.30e-02 | 43 |
GO:00706618 | Oral cavity | OSCC | leukocyte proliferation | 145/7305 | 318/18723 | 9.31e-03 | 3.33e-02 | 145 |
GO:004620915 | Oral cavity | OSCC | nitric oxide metabolic process | 42/7305 | 81/18723 | 1.27e-02 | 4.24e-02 | 42 |
GO:00027022 | Oral cavity | OSCC | positive regulation of production of molecular mediator of immune response | 58/7305 | 117/18723 | 1.28e-02 | 4.27e-02 | 58 |
GO:00024441 | Oral cavity | OSCC | myeloid leukocyte mediated immunity | 50/7305 | 99/18723 | 1.31e-02 | 4.34e-02 | 50 |
GO:00454298 | Oral cavity | OSCC | positive regulation of nitric oxide biosynthetic process | 23/7305 | 40/18723 | 1.36e-02 | 4.50e-02 | 23 |
GO:00466517 | Oral cavity | OSCC | lymphocyte proliferation | 131/7305 | 288/18723 | 1.41e-02 | 4.67e-02 | 131 |
GO:0055094 | Oral cavity | OSCC | response to lipoprotein particle | 20/7305 | 34/18723 | 1.51e-02 | 4.91e-02 | 20 |
GO:00706657 | Oral cavity | OSCC | positive regulation of leukocyte proliferation | 72/7305 | 150/18723 | 1.53e-02 | 4.95e-02 | 72 |
GO:1903320110 | Oral cavity | LP | regulation of protein modification by small protein conjugation or removal | 111/4623 | 242/18723 | 4.81e-13 | 4.30e-11 | 111 |
GO:004312316 | Oral cavity | LP | positive regulation of I-kappaB kinase/NF-kappaB signaling | 88/4623 | 186/18723 | 1.58e-11 | 1.13e-09 | 88 |
GO:001050615 | Oral cavity | LP | regulation of autophagy | 132/4623 | 317/18723 | 1.82e-11 | 1.28e-09 | 132 |
GO:0009896110 | Oral cavity | LP | positive regulation of catabolic process | 187/4623 | 492/18723 | 2.30e-11 | 1.58e-09 | 187 |
GO:0031396110 | Oral cavity | LP | regulation of protein ubiquitination | 95/4623 | 210/18723 | 5.88e-11 | 3.61e-09 | 95 |
GO:0031331110 | Oral cavity | LP | positive regulation of cellular catabolic process | 163/4623 | 427/18723 | 3.03e-10 | 1.59e-08 | 163 |
GO:0043254110 | Oral cavity | LP | regulation of protein-containing complex assembly | 163/4623 | 428/18723 | 3.72e-10 | 1.92e-08 | 163 |
GO:000961516 | Oral cavity | LP | response to virus | 143/4623 | 367/18723 | 7.42e-10 | 3.52e-08 | 143 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa05160 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa051351 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa054171 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa051601 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa051352 | Colorectum | SER | Yersinia infection | 43/1580 | 137/8465 | 2.15e-04 | 2.10e-03 | 1.52e-03 | 43 |
hsa04217 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
hsa054172 | Colorectum | SER | Lipid and atherosclerosis | 55/1580 | 215/8465 | 6.83e-03 | 3.77e-02 | 2.74e-02 | 55 |
hsa051353 | Colorectum | SER | Yersinia infection | 43/1580 | 137/8465 | 2.15e-04 | 2.10e-03 | 1.52e-03 | 43 |
hsa042171 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
hsa054173 | Colorectum | SER | Lipid and atherosclerosis | 55/1580 | 215/8465 | 6.83e-03 | 3.77e-02 | 2.74e-02 | 55 |
hsa051354 | Colorectum | MSS | Yersinia infection | 53/1875 | 137/8465 | 7.73e-06 | 8.93e-05 | 5.47e-05 | 53 |
hsa054174 | Colorectum | MSS | Lipid and atherosclerosis | 70/1875 | 215/8465 | 2.38e-04 | 1.81e-03 | 1.11e-03 | 70 |
hsa051602 | Colorectum | MSS | Hepatitis C | 52/1875 | 157/8465 | 9.29e-04 | 5.58e-03 | 3.42e-03 | 52 |
hsa05167 | Colorectum | MSS | Kaposi sarcoma-associated herpesvirus infection | 60/1875 | 194/8465 | 2.59e-03 | 1.27e-02 | 7.81e-03 | 60 |
hsa05161 | Colorectum | MSS | Hepatitis B | 48/1875 | 162/8465 | 1.53e-02 | 4.93e-02 | 3.02e-02 | 48 |
hsa051355 | Colorectum | MSS | Yersinia infection | 53/1875 | 137/8465 | 7.73e-06 | 8.93e-05 | 5.47e-05 | 53 |
hsa054175 | Colorectum | MSS | Lipid and atherosclerosis | 70/1875 | 215/8465 | 2.38e-04 | 1.81e-03 | 1.11e-03 | 70 |
hsa051603 | Colorectum | MSS | Hepatitis C | 52/1875 | 157/8465 | 9.29e-04 | 5.58e-03 | 3.42e-03 | 52 |
Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TICAM1 | SNV | Missense_Mutation | c.1231N>T | p.Arg411Trp | p.R411W | Q8IUC6 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
TICAM1 | SNV | Missense_Mutation | c.1381N>C | p.Asp461His | p.D461H | Q8IUC6 | protein_coding | deleterious(0.01) | possibly_damaging(0.686) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
TICAM1 | SNV | Missense_Mutation | novel | c.868N>C | p.Thr290Pro | p.T290P | Q8IUC6 | protein_coding | tolerated(1) | benign(0) | TCGA-AR-A255-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
TICAM1 | deletion | Frame_Shift_Del | novel | c.183_190delAGAGGCAT | p.Ala63GlyfsTer40 | p.A63Gfs*40 | Q8IUC6 | protein_coding | TCGA-AR-A2LR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
TICAM1 | insertion | Frame_Shift_Ins | rs762126373 | c.1925_1926insC | p.Pro643ThrfsTer123 | p.P643Tfs*123 | Q8IUC6 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
TICAM1 | deletion | Frame_Shift_Del | novel | c.455delN | p.Pro152GlnfsTer102 | p.P152Qfs*102 | Q8IUC6 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
TICAM1 | SNV | Missense_Mutation | novel | c.892N>G | p.Thr298Ala | p.T298A | Q8IUC6 | protein_coding | tolerated(0.53) | benign(0.006) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TICAM1 | SNV | Missense_Mutation | rs757840131 | c.2008C>A | p.Pro670Thr | p.P670T | Q8IUC6 | protein_coding | tolerated(0.41) | benign(0.01) | TCGA-EA-A5ZF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
TICAM1 | SNV | Missense_Mutation | rs780257437 | c.484C>G | p.Leu162Val | p.L162V | Q8IUC6 | protein_coding | tolerated(0.36) | benign(0.006) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TICAM1 | SNV | Missense_Mutation | c.192G>C | p.Leu64Phe | p.L64F | Q8IUC6 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
148022 | TICAM1 | TRANSCRIPTION FACTOR | VACCINE | 18217948 |
Page: 1 |